Curis Lifesciences Quarterly Results for Trading Insights
Latest Quarter Net Profit
₹1 Cr
QJun 2024
In Jun 2024, Curis Lifesciences (CURIS) reported revenue ₹9 Cr and net profit ₹1 Cr. Check CURIS market cap trends to track the company's total market size over time.
Curis Lifesciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
CURIS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Jun 2024 | QoQ | YoY |
|---|---|---|---|
| Revenue (₹ Cr) | 9 | - | - |
| Net Profit (₹ Cr) | 1 | - | - |
| EBITDA (₹ Cr) | 3 | - | - |
| EPS (₹) | 24.00 | - | - |
| Operating Margin (%) | 30.0% | - | - |
CURIS Share Price Trend — 1-Year Movement Across Quarterly Results
Curis Lifesciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse CURIS shareholding pattern to track promoter, FII and institutional holdings.
CURIS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Curis Lifesciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹463,071.60 Cr | 1902.4 | 15,018 | 2,710 | -5.6% | - | 18.0% | 168.4 |
|
Divis Laboratories
Mar 2026 |
₹225,157.18 Cr | 8597.0 | 2,986 | 751 | -5.0% | - | 25.2% | 303.7 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4896.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 425.4 |
|
Cipla
Mar 2026 |
₹115,699.61 Cr | 1432.2 | 6,612 | 543 | -9.3% | - | 8.2% | 208.5 |
|
Zydus Life Science
Mar 2026 |
₹113,855.38 Cr | 1120.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 88.5 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores